Source comparison
Melanotan-2 Libido Enhancement Research: Comparison Table
Melanotan-2 (MT-2) MC4R receptor agonist in hypothalamus; central arousal pathway activation Psychogenic erectile dysfunction, hypoactive sexual desire disorder 30–90 minutes post-injection 60–72% improvement in men with psychogenic ED; 50% improvement in wome
This comparison does not assign a generated winner or score.
- Melanotan-2 (MT-2)
- MC4R receptor agonist in hypothalamus; central arousal pathway activation
- Psychogenic erectile dysfunction, hypoactive sexual desire disorder
- 30–90 minutes post-injection
- 60–72% improvement in men with psychogenic ED; 50% improvement in women with HSDD
- Nausea (60–80% at doses >5mg)
- Best evidence for central (brain-based) sexual dysfunction; narrow therapeutic window
- Sildenafil (Viagra)
- PDE5 inhibitor; increases cGMP in corpus cavernosum smooth muscle
- Vasculogenic erectile dysfunction, mild psychogenic ED
- 30–60 minutes oral
- 70–85% improvement in men with vasculogenic ED; minimal effect in pure psychogenic cases
- Headache (16%), flushing (10%)
- Gold standard for vascular ED; less effective when arousal is the primary issue
- Bremelanotide (Vyleesi)
- MC4R receptor agonist (similar to MT-2); FDA-approved for HSDD in premenopausal women
- Hypoactive sexual desire disorder (women only)
- 45 minutes subcutaneous
- 25% increase in satisfying sexual events vs placebo over 24 weeks
- Nausea (40%), flushing (20%)
- FDA-approved analog of melanotan-2 with better safety profile but lower efficacy
- Testosterone Replacement
- Androgen receptor activation; increases libido via multiple pathways
- Hypogonadal men (total testosterone <300 ng/dL)
- 2–4 weeks (depends on formulation)
- 60–70% improvement in libido when deficiency confirmed
- Polycythemia, acne, testicular atrophy
- Only effective when baseline testosterone is low. No benefit in eugonadal men
- Placebo (sham treatment)
- None (psychological expectation effects only)
- Control group in clinical trials
- Variable
- 18–30% report subjective improvement in most sexual dysfunction trials
- None
- Response rate establishes baseline for drug efficacy comparisons